CN106237158A - 一种治疗骨质疏松的药物组合物 - Google Patents
一种治疗骨质疏松的药物组合物 Download PDFInfo
- Publication number
- CN106237158A CN106237158A CN201610812366.8A CN201610812366A CN106237158A CN 106237158 A CN106237158 A CN 106237158A CN 201610812366 A CN201610812366 A CN 201610812366A CN 106237158 A CN106237158 A CN 106237158A
- Authority
- CN
- China
- Prior art keywords
- radix
- pharmaceutical composition
- herba
- aloe
- fine powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 43
- 230000001009 osteoporotic effect Effects 0.000 title claims abstract description 12
- 241001116389 Aloe Species 0.000 claims abstract description 35
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 35
- 238000002360 preparation method Methods 0.000 claims abstract description 35
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 35
- 241001533451 Ajuga ciliata Species 0.000 claims abstract description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims description 48
- 210000000988 bone and bone Anatomy 0.000 claims description 38
- 239000012141 concentrate Substances 0.000 claims description 26
- 239000000706 filtrate Substances 0.000 claims description 26
- 239000008187 granular material Substances 0.000 claims description 15
- 239000012567 medical material Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 244000025254 Cannabis sativa Species 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 abstract description 14
- 230000001629 suppression Effects 0.000 abstract description 5
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 4
- 238000000605 extraction Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 79
- 210000000689 upper leg Anatomy 0.000 description 23
- 239000011575 calcium Substances 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 229910052791 calcium Inorganic materials 0.000 description 16
- 239000011777 magnesium Substances 0.000 description 16
- 230000037182 bone density Effects 0.000 description 14
- 229910052749 magnesium Inorganic materials 0.000 description 14
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 13
- 229910052698 phosphorus Inorganic materials 0.000 description 13
- 229920002472 Starch Polymers 0.000 description 11
- 239000008107 starch Substances 0.000 description 11
- 235000019698 starch Nutrition 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 210000004291 uterus Anatomy 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000008021 deposition Effects 0.000 description 7
- 210000001672 ovary Anatomy 0.000 description 7
- 208000010392 Bone Fractures Diseases 0.000 description 6
- 206010017076 Fracture Diseases 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000013425 morphometry Methods 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 210000002303 tibia Anatomy 0.000 description 4
- YCIHPQHVWDULOY-FMZCEJRJSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O YCIHPQHVWDULOY-FMZCEJRJSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 206010046764 Uterine atrophy Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000001215 fluorescent labelling Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000002594 sorbent Substances 0.000 description 3
- 206010041569 spinal fracture Diseases 0.000 description 3
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 2
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010010214 Compression fracture Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000173166 Pyrus ussuriensis Species 0.000 description 1
- 235000011572 Pyrus ussuriensis Nutrition 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010072005 Spinal pain Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- -1 hydroxy-propyl Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 108010068072 salmon calcitonin Proteins 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- JHJUUEHSAZXEEO-UHFFFAOYSA-M sodium;4-dodecylbenzenesulfonate Chemical group [Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1 JHJUUEHSAZXEEO-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种治疗骨质疏松的药物组合物及其制备方法,该药物组合物由以下重量份的药物按以下步骤制成:将苦玄参、天竺黄、三棵针、天葵子、石榴子、丛菔、白薇、芦荟、垂盆草、萹蓄、杜仲、筋骨草通过醇提、水煮工艺制成,通过药效学试验证明本发明药物组合物可不同程度的抑制骨质疏松和治疗骨质疏松的作用。
Description
技术领域
本发明涉及医药发明领域,具体涉及一种治疗骨质疏松的的药物组合物及其制备方法。
背景技术
骨质疏松(osteoporosis,OP)是一种以低骨量和骨组织微结构破坏为特征,导致骨质脆性增加和易于骨折的全身性骨代谢性疾病。本病常见于老年人,但各年龄时期均可发病。骨质疏松可分为原发性和继发性两类。原发性骨质疏松系指不伴引起本病的其他疾患;继发性骨质疏松则是由于各种全身性或内分泌代谢性疾病引起的骨组织量减少。此外,按发生部位亦可分为局限性或泛发性骨质疏松。无并发症的骨质疏松症本身,并无疼痛等症状,也无畸形等体征。早期发现本病依靠骨密度检查。椎体X线平片异常迟于骨密度提示,但是早于症状体征的提示。常常在不知不觉中发生椎体压缩骨折,也可因咳嗽、打喷嚏、轻微外伤等诱发椎体骨折。椎体骨折的数周内,出现局部疼痛,体征出现叩击痛。多个椎体压缩者,出现驼背(罗锅),身高变矮。非椎体骨折时,疼痛和畸形表现更加严重。
骨质疏松症是一种十分严重的疾病,其治疗费用也是相当高,仅在美国,一年所花的医药费就达7-10万亿美元,随着老龄化社会的到来,原发性骨质疏松症的发病率明显上升,骨质疏松症骨折成为临床常见的损伤性疾病,极易造成骨延迟愈合和不愈合而致残。其发病原因一般认为与钙或营养缺乏,内分泌功能紊乱以及运动不足等因素有关,国内外学者虽提出许多治疗方案,但是迄今为止仍未获得十分有效的治疗措施。
为了解决上述问题,本发明人研发了一种新的治疗骨质疏松的药物组合物及制备方法。
发明内容
本发明的目的是提供一种治疗骨质疏松的的药物组合物。
本发明的另一目的是提供一种治疗骨质疏松的药物组合物的制备方法。
本发明提供一种治疗骨质疏松的药物组合物,该药物组合物由以下重量份的药物制成:苦玄参15-50份、天竺黄10-50份、三棵针10-45份、天葵子10-40份、石榴子20-60份、丛菔10-50份、白薇15-60份、芦荟20-70份、垂盆草15-55份、篇蓄10-40份、杜仲20-60份、筋骨草10-45份。
优选的,本发明所述的药物组合物由以下重量份的药物制成:苦玄参20-45份、天竺黄15-45份、三棵针15-40份、天葵子13-37份、石榴子25-55份、丛菔15-45份、白薇20-55份、芦荟30-60份、垂盆草20-50份、篇蓄15-35份、杜仲25-55份、筋骨草15-40份。
进一步优选的,本发明所述的药物组合物由以下重量份的药物制成:苦玄参25-40份、天竺黄20-40份、三棵针20-35份、天葵子18-32份、石榴子30-50份、丛菔20-40份、白薇25-50份、芦荟35-55份、垂盆草25-45份、篇蓄18-32份、杜仲30-50份、筋骨草20-35份。
更进一步优选的,本发明所述的药物组合物由以下重量份的药物制成:苦玄参28-37份、天竺黄25-35份、三棵针24-32份、天葵子21-29份、石榴子35-45份、丛菔25-35份、白薇30-45份、芦荟40-50份、垂盆草30-40份、篇蓄22-28份、杜仲35-45份、筋骨草23-32份。
更进一步优选的,本发明所述的药物组合物由以下重量份的药物制成:苦玄参33份、天竺黄30份、三棵针28份、天葵子25份、石榴子40份、丛菔30份、白薇37份、芦荟45份、垂盆草35份、篇蓄25份、杜仲40份、筋骨草28份。
本发明所述的药物组合物还含有药学上可接受的载体或稀释剂。
本发明所述的药物组合物为固体制剂或液体制剂,所述固体制剂为片剂、胶囊剂、颗粒剂或丸剂;所述液体制剂为口服液。
本发明所述药物组合物的制备方法包括以下步骤:将苦玄参、天竺黄、三棵针、天葵子、石榴子、丛菔、白薇、芦荟、垂盆草、篇蓄、杜仲、筋骨草粉碎过筛,与药学上可接受的载体或稀释剂混合均匀,制备成制剂。
本发明所述药物组合物的制备方法包括以下步骤:
1)按配比称取重量份的药材备用;
2)将苦玄参、天竺黄、三棵针、天葵子、石榴子、丛菔加3-6倍量的水煎煮1-3小时,过滤,滤液浓缩,干燥,粉碎成细粉,备用;
3)将白薇、芦荟、垂盆草、篇蓄、杜仲、筋骨草加2-5倍量75%的乙醇浸泡3-7小时,过滤,滤液浓缩干燥,粉碎成细粉,备用;
4)将上述细粉混匀,加入辅料制成药学上可接收的剂型。
优选的,本发明所述药物组合物的制备方法包括以下步骤:
1)按配比称取重量份的药材备用;
2)将苦玄参、天竺黄、三棵针、天葵子、石榴子、丛菔加5倍量的水煎煮2小时,过滤,滤液浓缩,干燥,粉碎成细粉,备用;
3)将白薇、芦荟、垂盆草、篇蓄、杜仲、筋骨草加4倍量75%的乙醇浸泡5小时,过滤,滤液浓缩干燥,粉碎成细粉,备用;
4)将上述细粉混匀,加入辅料制成药学上可接收的剂型。
所述重量份数可以是μg、mg、g、kg等医药领域公知的重量单位。
倍量的含义是指药材的重量比。
本发明提供的药物组合物还含有药学上可接受的载体或稀释剂
所述药物组合物为固体制剂或液体制剂,所述固体制剂为片剂、胶囊剂、颗粒剂或丸剂;所述液体制剂为口服液。
所述药学上可接受的载体或稀释剂是指药学领域常规的药物载体,选自填充剂、粘合剂、崩解剂、润滑剂、表面活性剂或矫味剂中的一种或几种。
其中所述填充剂选自淀粉、蔗糖、乳糖、甘露醇、山梨醇、木糖醇、微晶纤维素或葡萄糖等;
所述粘合剂选自纤维素衍生物、藻酸盐、明胶或聚乙烯吡咯烷酮等;
所述崩解剂选自微晶纤维素、羧甲基淀粉钠、聚乙烯吡咯烷酮、低取代羟丙基纤维素或交联羧甲基纤维素钠;
所述润滑剂选自硬脂酸、聚乙二醇、碳酸钙、碳酸氢钠、二氧化硅、滑石粉或硬脂酸镁;
所述表面活性剂选自十二烷基苯磺酸钠、硬脂酸、聚氧乙烯-聚氧丙烯共聚物、脂肪酸山梨坦或聚山梨酯(吐温)等;
所述矫味剂选自阿斯巴甜、蔗糖素或糖精钠。
本发明提供的治疗骨质疏松的药物组合物具有以下有益效果:
通过药效学试验证明:1、本发明对子宫萎缩有明显改善、大鼠的子宫系数明显增加;2、模型组股骨远端骨密度和椎骨骨密度明显降低;3、大鼠股骨远端骨密度和椎骨骨密度有不同程度的增加;4、大鼠骨小梁体积明显减小;骨小梁吸收表面、形成表面、骨矿化沉积率有不同程度增加;5、股骨颈最大载荷有明显增加;能增加去卵巢大鼠的股骨颈强度;血清钙略有增加;6、血清P和Mg含量略有提高;7、去卵巢后大鼠的骨形成和骨吸收均显著增加,骨转换加快;8、大鼠股骨中的Ca、P、Mg显著增加。
提示本发明提供的药物组合物可不同程度的抑制骨质疏松和治疗骨质疏松的作用。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。
实施例1
组方:苦玄参15g、天竺黄10g、三棵针10g、天葵子10g、石榴子20g、丛菔10g、白薇15g、芦荟20g、垂盆草15g、篇蓄10g、杜仲20g、筋骨草10g。
制备方法:
1)按配比称取重量份的药材备用;
2)将苦玄参、天竺黄、三棵针、天葵子、石榴子、丛菔加3倍量的水煎煮1小时,过滤,滤液浓缩,干燥,粉碎成细粉,备用;
3)将白薇、芦荟、垂盆草、篇蓄、杜仲、筋骨草加2倍量75%的乙醇浸泡3小时,过滤,滤液浓缩干燥,粉碎成细粉,备用;
4)将上述细粉混匀,加入占混合均匀细粉重量2/9的淀粉,装入胶囊,制成胶囊剂。
实施例2
组方:苦玄参50g、天竺黄50g、三棵针45g、天葵子40g、石榴子60g、丛菔50g、白薇60g、芦荟70g、垂盆草55g、篇蓄40g、杜仲60g、筋骨草45g。
制备方法:
1)按配比称取重量份的药材备用;
2)将苦玄参、天竺黄、三棵针、天葵子、石榴子、丛菔加4倍量的水煎煮3小时,过滤,滤液浓缩,干燥,粉碎成细粉,备用;
3)将白薇、芦荟、垂盆草、篇蓄、杜仲、筋骨草加3倍量75%的乙醇浸泡7小时,过滤,滤液浓缩干燥,粉碎成细粉,备用;
4)将上述细粉混匀,加入占混合均匀细粉重量2/9的淀粉,装入胶囊,制成胶囊剂。
实施例3
组方:苦玄参20g、天竺黄15g、三棵针15g、天葵子13g、石榴子25g、丛菔15g、白薇20g、芦荟30g、垂盆草20g、篇蓄15g、杜仲25g、筋骨草15g。
制备方法:
1)按配比称取重量份的药材备用;
2)将苦玄参、天竺黄、三棵针、天葵子、石榴子、丛菔加4倍量的水煎煮1-3小时,过滤,滤液浓缩,干燥,粉碎成细粉,备用;
3)将白薇、芦荟、垂盆草、篇蓄、杜仲、筋骨草加3倍量75%的乙醇浸泡4小时,过滤,滤液浓缩干燥,粉碎成细粉,备用;
4)将上述细粉混匀,加入占混合均匀细粉重量1/5的淀粉,干燥,压片,即得本申请的片剂。
实施例4
组方:苦玄参45g、天竺黄45g、三棵针40g、天葵子37g、石榴子55g、丛菔45g、白薇55g、芦荟60g、垂盆草50g、篇蓄35g、杜仲55g、筋骨草40g。
制备方法:
1)按配比称取重量份的药材备用;
2)将苦玄参、天竺黄、三棵针、天葵子、石榴子、丛菔加5倍量的水煎煮1-3小时,过滤,滤液浓缩,干燥,粉碎成细粉,备用;
3)将白薇、芦荟、垂盆草、篇蓄、杜仲、筋骨草加4倍量75%的乙醇浸泡6小时,过滤,滤液浓缩干燥,粉碎成细粉,备用;
4)将上述细粉混匀,加入占混合均匀细粉重量1/5的淀粉,混匀,制粒,干燥,整粒,得到本申请的颗粒剂。
实施例5
组方:苦玄参25g、天竺黄20g、三棵针20g、天葵子18g、石榴子30g、丛菔20g、白薇25g、芦荟35g、垂盆草25g、篇蓄18g、杜仲30g、筋骨草20g。
制备方法:
1)按配比称取重量份的药材备用;
2)将苦玄参、天竺黄、三棵针、天葵子、石榴子、丛菔加5倍量的水煎煮2小时,过滤,滤液浓缩,干燥,粉碎成细粉,备用;
3)将白薇、芦荟、垂盆草、篇蓄、杜仲、筋骨草加4倍量75%的乙醇浸泡5小时,过滤,滤液浓缩干燥,粉碎成细粉,备用;
4)将上述细粉混匀,加入占混合均匀细粉重量1/5的淀粉,混匀,制粒,干燥,整粒,得到本申请的颗粒剂。
实施例6
组方:苦玄参40g、天竺黄40g、三棵针35g、天葵子32g、石榴子50g、丛菔40g、白薇50g、芦荟55g、垂盆草45g、篇蓄32g、杜仲50g、筋骨草35g。
制备方法:
1)按配比称取重量份的药材备用;
2)将苦玄参、天竺黄、三棵针、天葵子、石榴子、丛菔加5倍量的水煎煮2小时,过滤,滤液浓缩,干燥,粉碎成细粉,备用;
3)将白薇、芦荟、垂盆草、篇蓄、杜仲、筋骨草加4倍量75%的乙醇浸泡5小时,过滤,滤液浓缩干燥,粉碎成细粉,备用;
4)将上述细粉混匀,加入占混合均匀细粉重量1/5的淀粉,混匀,制粒,干燥,整粒,得到本申请的颗粒剂。
实施例7
组方:苦玄参28g、天竺黄25g、三棵针24g、天葵子21g、石榴子35g、丛菔25g、白薇30g、芦荟40g、垂盆草30g、篇蓄22g、杜仲35g、筋骨草23g。
制备方法:
1)按配比称取重量份的药材备用;
2)将苦玄参、天竺黄、三棵针、天葵子、石榴子、丛菔加5倍量的水煎煮2小时,过滤,滤液浓缩,干燥,粉碎成细粉,备用;
3)将白薇、芦荟、垂盆草、篇蓄、杜仲、筋骨草加4倍量75%的乙醇浸泡5小时,过滤,滤液浓缩干燥,粉碎成细粉,备用;
4)将上述细粉混匀,加入占混合均匀细粉重量1/5的淀粉,混匀,制粒,干燥,整粒,得到本申请的颗粒剂。
实施例8
组方:苦玄参37g、天竺黄35g、三棵针32g、天葵子29g、石榴子45g、丛菔35g、白薇45g、芦荟50g、垂盆草40g、篇蓄28g、杜仲45g、筋骨草32g。
制备方法:
1)按配比称取重量份的药材备用;
2)将苦玄参、天竺黄、三棵针、天葵子、石榴子、丛菔加5倍量的水煎煮2小时,过滤,滤液浓缩,干燥,粉碎成细粉,备用;
3)将白薇、芦荟、垂盆草、篇蓄、杜仲、筋骨草加4倍量75%的乙醇浸泡5小时,过滤,滤液浓缩干燥,粉碎成细粉,备用;
4)将上述细粉混匀,加入占混合均匀细粉重量1/5的淀粉,混匀,制粒,干燥,整粒,得到本申请的颗粒剂。
实施例9
组方:苦玄参33g、天竺黄30g、三棵针28g、天葵子25g、石榴子40g、丛菔30g、白薇37g、芦荟45g、垂盆草35g、篇蓄25g、杜仲40g、筋骨草28g。
制备方法:
1)按配比称取重量份的药材备用;
2)将苦玄参、天竺黄、三棵针、天葵子、石榴子、丛菔加5倍量的水煎煮2小时,过滤,滤液浓缩,干燥,粉碎成细粉,备用;
3)将白薇、芦荟、垂盆草、篇蓄、杜仲、筋骨草加4倍量75%的乙醇浸泡5小时,过滤,滤液浓缩干燥,粉碎成细粉,备用;
4)将上述细粉混匀,加入占混合均匀细粉重量1/5的淀粉,混匀,制粒,干燥,整粒,得到本申请的颗粒剂。
为了进一步证明本发明的有益效果,发明人进行了药效学试验
对去卵巢致大鼠骨质疏松症的影响
1、实验动物:2月龄Wistar大鼠,雌性,体重180-200g。
2、实验药物:
实施例1的药物组合物;青霉素;盐酸四环素;密盖息。
3、实验分组:
假手术组、模型组、实施例1高剂量组(实施例1制备的药物2g/kg)、实施例1中剂量组(实施例1制备的药物1g/kg)、实施例1低剂量组(实施例1制备的药物0.5g/kg)。
4、试验方法:
动物购入后,称重,按体重随机分笼,每笼5只。饲养5周后,当大鼠3月龄时,进行卵巢切除的手术,选取10只为假手术组,其余均接受卵巢切除术。将大鼠称重,以1.1%戊巴比妥钠(40mg/kg,4ml/kg)腹腔注射麻醉,将麻醉好的大鼠仰卧位固定,腹部用酒精消毒,无菌条件下在下腹部剪开2cm左右的切口,以无菌的眼科镊沿子宫和输卵管寻找,可见乳白色发亮的脂肪团,分离脂肪团,可见粉红色卵巢,将卵巢下输卵管用手术线结扎,摘除卵巢。同法摘除另一侧卵巢。10只假手术组,同法手术暴露卵巢,只切除少量脂肪组织,关闭腹腔,伤口局部敷青霉素,分别缝合肌肉层和皮肤,酒精消毒伤口,术后腹腔注射青霉素(4万单位/只/天),连续3天。手术后将大鼠放回笼中饲养,正常饮食。
各组按大鼠给药容积0.5ml/100g,用0.5%的羧甲基纤维素钠(CMC)配成混悬液,以0.5%的CMC为溶剂对照。术后2天开始给药,假手术组、模型组给予0.5%的CMC。每日灌胃一次,连续灌胃80天。每周称一次大鼠体重,并调整给药剂量。每次配制1周的给药量,4℃保存,灌胃前将药品拿出温浴,摇匀。
所有动物在处死前第13天腹腔注射盐酸四环素30mg/kg,作为第一次荧光标记;处死前第3天再注射一次盐酸四环素作为第二次荧光标记,两次荧光标记间隔时间为10天。
在荧光显微镜下,沉积在骨表面的四环素荧光呈黄绿色,此方法可动态观察骨小梁的矿化沉积率,反映成骨细胞骨形成情况。
5、实验结果:
(一)对去势大鼠子宫指数的影响:见表1。
表1:对去势大鼠模型子宫指数的影响
(组别) | 剂量(g/kg) | 动物数(只) | 子宫指数(%) |
假手术组 | - | 10 | 1.79±0.31** |
模型组 | - | 10 | 0.29±0.15** |
密盖息组 | 0.05(mg) | 10 | 0.75±0.25##※ |
实施例1高剂量组 | 2 | 10 | 0.54±0.11#※ |
实施例1中剂量组 | 1 | 10 | 0.53±0.16#※ |
实施例1低剂量组 | 0.5 | 10 | 0.47±0.04 |
注:与假手术组相比,**P<0.01;与模型组相比,#P<0.05,##P<0.01,###P<0.001.
表1结果显示:与假手术组比较,模型组大鼠的子宫明显萎缩,子宫指数有显著性差异(P<0.01);与模型组相比,密盖息组大鼠的子宫由于雌激素的刺激大鼠子宫指数显著增加(P<0.01),实施例1中、高剂量组子宫萎缩有明显改善(P<0.05);除实施例1低剂量组外,其余各组大鼠的子宫系数明显增加(P<0.05)。
(二)对去势大鼠股骨远端、腰椎骨骨密度的影响:见表2。
表2:对去势大鼠股骨远端、腰椎骨骨密度的影响
注:与假手术组相比,**P<0.01;与模型组比较#P<0.05,##P<0.01;
表2显示:与假手术组相比,模型组股骨远端骨密度和椎骨骨密度明显降低(P<0.01);与模型组相比,实施例1中剂量组和高剂量组大鼠股骨远端骨密度和椎骨骨密度有不同程度的增加(P<0.01,P<0.05);
(三)对去势大鼠胫骨近端骨小梁形态计量学的影响:见表3。
表3:对去势大鼠胫骨近端骨小梁形态计量学的影响
注:与假手术组相比,**P<0.01;与模型组比较#P<0.05,##P<0.01;
表3显示:骨小梁体积:与假手术组相比,模型组大鼠骨小梁体积明显减小(P<0.01);与模型组相比,密盖息组、实施例1中剂量组、高剂量组的骨小梁体积有不同程度增加(P<0.05,P<0.01)。
骨小梁吸收表面、形成表面、骨矿化沉积率:与假手术组相比,模型组明显增加(P<0.01);与模型组相比,密盖息组、实施例1中剂量组和高剂量组有不同程度的降低(P<0.05,P<0.01)。
(四)对去势大鼠胫骨近端骨皮质形态计量学的影响:见表4。
表4:对去势大鼠胫骨近端骨皮质形态计量学的影响
表4结果显示:骨矿化沉积率:与假手术组相比,模型组的骨矿化沉积率降低,没有明显差异(P>0.05);与模型组相比,各组骨矿化沉积率无明显差异;
皮质骨类骨质宽度:与假手术组相比,模型组的骨矿化沉积率升高,没有明显差异(P>0.05);与模型组相比,各组骨矿化沉积率无明显差异。
(五)对去势大鼠股骨干生物力学性能的影响:见表5。
表5:去势大鼠股骨干生物力学性能的影响
组别 | 剂量(g/kg) | 动物数(只) | 最大载荷(N) | 断裂挠度(mm) |
假手术组 | - | 10 | 88.1±10.1 | 0.571±0.093 |
模型组 | - | 10 | 84.2±7.5 | 0.551±0.082 |
密盖息组 | 0.05(mg) | 10 | 85.2±10.3 | 0.531±0.102 |
实施例1低剂量组 | 0.5 | 10 | 85.2±8.1 | 0.551±0.054 |
实施例1中剂量组 | 1 | 10 | 88.3±9.2 | 0.541±0.071 |
实施例1高剂量组 | 2 | 10 | 86.3±8.3 | 0.556±0.061 |
表5中骨生物力学参数显示:各组最大载荷、断裂挠度比较无明显差异。表明去卵巢3个月后,股骨干生物力学性能无明显变化。
(六)对去势大鼠股骨颈生物力学性能的影响:见表6。
表6:对去势大鼠股骨颈生物力学性能的影响
注:与假手术组相比,**P<0.01;与模型组比较#P<0.05,##P<0.01;
由表6可以看出:最大载荷:与假手术组相比,去卵巢后模型组股骨颈最大载荷显著降低(P<0.01);与模型组相比,密盖息组、实施例1中、高剂量组组有明显增加(P<0.05)。
断裂挠度:与假手术组相比,模型组的虽然有降低,但无明显差异(P>0.05);与模型组相比,实施例1高剂量组有明星增加(P<0.05),其余各组无明显差别(P>0.05)。
提示:实施例1中、高、低剂量组均能增加去卵巢大鼠的股骨颈强度,提示对骨质疏松股骨颈骨折有一定的保护作用。
(七)对去势大鼠血清中Ca、P、Mg浓度的影响:见表7。
表7:对去势大鼠血清中Ca、P、Mg浓度的影响
组别 | 剂量 | 动物数(只) | 血清钙(mmol/L) | 血清磷(mmol/L) | 血清镁(mg/dl) |
假手术组 | - | 10 | 2.27±0.13 | 1.91±0.17 | 2.5±0.2 |
模型组 | - | 10 | 2.13±0.11** | 1.73±0.12 | 2.3±0.1 |
密盖息组 | 0.05(mg) | 10 | 2.07±0.13 | 1.87±0.24 | 2.4±0.2 |
实施例1低剂量 | 0.5 | 10 | 2.13±0.11 | 1.72±0.25 | 2.5±0.2 |
实施例1中剂量 | 1 | 10 | 2.11±0.10 | 1.75±0.17 | 2.4±0.1 |
实施例1高剂量 | 2 | 10 | 2.16±0.15 | 1.81±0.41 | 2.3±0.1 |
注:与假手术组相比,**P<0.01。
表7显示:血清钙(Ca):与假手术组相比,模型组大鼠血清钙有明显降低(P<0.01);与模型组相比,实施例各组的血清钙略有增加,但无明显差异(P>0.05);。
血清磷(P)和镁(Mg):与假手术组比较,模型组血清P和Mg含量略有降低,但各组间无显著差异(P>0.05);与模型组相比,密盖息组、实验组各组血清P和Mg含量略有提高,但是变化不明显(P>0.05)。
(八)对去势大鼠血清中AKP活性和NTX含量的影响:见表8。
表8:对去势大鼠血清中AKP活性和NTX含量的影响
组别 | 剂量(g/kg) | 动物数(只) | 血清AKP(U/L) | 血清NTX(μg/L) |
假手术组 | - | 10 | 28.5±11.8 | 2.805±1.151 |
模型组 | - | 10 | 45.1±10.5** | 5.143±1.529** |
密盖息组 | 0.05(mg) | 10 | 35.2±9.1# | 2.771±0.652## |
实施例1低剂量组 | 0.5 | 10 | 41.2±11.3 | 3.868±0.772# |
实施例1中剂量组 | 1 | 10 | 34.2±8.1#※ | 3.473±1.141#※ |
实施例1高剂量组 | 2 | 10 | 30.3±12.1##※ | 3.022±1.071##※ |
注:与假手术组相比,**P<0.01;与模型组比较#P<0.05,##P<0.01。
表8显示:与假手术组比较,模型组大鼠的碱性磷酸酶(AKP)活性显著升高(P<0.01);I型胶原氨基交联末端肽(NTX)浓度明显增加(P<0.01),提示去卵巢后大鼠的骨形成和骨吸收均显著增加,骨转换加快。
与模型组相比:密盖息组和实施例1中剂量组大鼠AKP活性明显降低(P<0.05),实施例1中、高剂量组组AKP活性显著降低(P<0.01);。
与模型组相比:密盖息组和实施例1高剂量组的NTX活性显著降低(P<0.01),实施例1中、高剂量组大鼠NTX活性明显降低(P<0.05);
提示:本发明的产品剂量依赖性的抑制骨形成和骨吸收,抑制骨转化。
(九)对去势大鼠股骨中常量元素Ca、P、Mg含量的影响:见表9。
表9:对去势大鼠股骨中常量元素Ca、P、Mg含量的影响
注:与假手术组相比,**P<0.01;与模型组比较#P<0.05,##P<0.01。
表9结果显示:与假手术组比较,模型组大鼠股骨中的Ca、P、Mg含量明显降低(P<0.01);与模型组相比,密盖息组、实施例1高剂量组大鼠股骨中的Ca、P、Mg显著增加(P<0.01),实施例1中高剂量组大鼠股骨中的Ca、P、Mg明显增加(P<0.05)。
实验小结:
通过药效学试验证明:1、本发明对子宫萎缩有明显改善、大鼠的子宫系数明显增加;2、模型组股骨远端骨密度和椎骨骨密度明显降低;3、大鼠股骨远端骨密度和椎骨骨密度有不同程度的增加;4、大鼠骨小梁体积明显减小;骨小梁吸收表面、形成表面、骨矿化沉积率有不同程度增加;5、股骨颈最大载荷有明显增加;能增加去卵巢大鼠的股骨颈强度;血清钙略有增加;6、血清P和Mg含量略有提高;7、去卵巢后大鼠的骨形成和骨吸收均显著增加,骨转换加快;8、大鼠股骨中的Ca、P、Mg显著增加。
提示本发明提供的药物组合物可不同程度的抑制骨质疏松和具有治疗骨质疏松的作用。
虽然,上文中已经用一般性说明、具体实施方式及试验,对本发明作了详尽的描述,但在本发明基础上,可以对之作出一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (10)
1.一种治疗骨质疏松的药物组合物,其特征在于,该药物组合物由以下重量份的药物制成:苦玄参15-50份、天竺黄10-50份、三棵针10-45份、天葵子10-40份、石榴子20-60份、丛菔10-50份、白薇15-60份、芦荟20-70份、垂盆草15-55份、萹蓄10-40份、杜仲20-60份、筋骨草10-45份。
2.根据权利要求1所述的药物组合物,其特征在于,该药物组合物由以下重量份的药物制成:苦玄参20-45份、天竺黄15-45份、三棵针15-40份、天葵子13-37份、石榴子25-55份、丛菔15-45份、白薇20-55份、芦荟30-60份、垂盆草20-50份、萹蓄15-35份、杜仲25-55份、筋骨草15-40份。
3.根据权利要求2所述的药物组合物,其特征在于,该药物组合物由以下重量份的药物制成:苦玄参25-40份、天竺黄20-40份、三棵针20-35份、天葵子18-32份、石榴子30-50份、丛菔20-40份、白薇25-50份、芦荟35-55份、垂盆草25-45份、萹蓄18-32份、杜仲30-50份、筋骨草20-35份。
4.根据权利要求3所述的药物组合物,其特征在于,该药物组合物由以下重量份的药物制成:苦玄参28-37份、天竺黄25-35份、三棵针24-32份、天葵子21-29份、石榴子35-45份、丛菔25-35份、白薇30-45份、芦荟40-50份、垂盆草30-40份、萹蓄22-28份、杜仲35-45份、筋骨草23-32份。
5.根据权利要求4所述的药物组合物,其特征在于,该药物组合物由以下重量份的药物制成:苦玄参33份、天竺黄30份、三棵针28份、天葵子25份、石榴子40份、丛菔30份、白薇37份、芦荟45份、垂盆草35份、萹蓄25份、杜仲40份、筋骨草28份。
6.根据权利要求1-5任一项所述的药物组合物,其特征在于,该药物组合物还含有药学上可接受的载体或稀释剂。
7.根据权利要求6所述的药物组合物,其特征在于,所述药物组合物为固体制剂或液体制剂,所述固体制剂为片剂、胶囊剂、颗粒剂或丸剂;所述液体制剂为口服液。
8.一种制备权利要求1-5任一项所述的药物组合物的方法,其特征在于,该方法包括以下步骤:将苦玄参、天竺黄、三棵针、天葵子、石榴子、丛菔、白薇、芦荟、垂盆草、萹蓄、杜仲、筋骨草粉碎过筛,与药学上可接受的载体或稀释剂混合均匀,制备成制剂。
9.一种制备权利要求1-5任一项所述的药物组合物的方法,其特征在于,该方法包括以下步骤:
1)按配比称取重量份的药材备用;
2)将苦玄参、天竺黄、三棵针、天葵子、石榴子、丛菔加3-6倍量的水煎煮1-3小时,过滤,滤液浓缩,干燥,粉碎成细粉,备用;
3)将白薇、芦荟、垂盆草、萹蓄、杜仲、筋骨草加2-5倍量75%的乙醇浸泡3-7小时,过滤,滤液浓缩干燥,粉碎成细粉,备用;
4)将上述细粉混匀,加入辅料制成药学上可接收的剂型。
10.根据权利要求9所述药物组合物的制备方法,其特征在于,该方法包括以下步骤:
1)按配比称取重量份的药材备用;
2)将苦玄参、天竺黄、三棵针、天葵子、石榴子、丛菔加5倍量的水煎煮2小时,过滤,滤液浓缩,干燥,粉碎成细粉,备用;
3)将白薇、芦荟、垂盆草、萹蓄、杜仲、筋骨草加4倍量75%的乙醇浸泡5小时,过滤,滤液浓缩干燥,粉碎成细粉,备用;
4)将上述细粉混匀,加入辅料制成药学上可接收的剂型。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610812366.8A CN106237158A (zh) | 2016-08-30 | 2016-08-30 | 一种治疗骨质疏松的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610812366.8A CN106237158A (zh) | 2016-08-30 | 2016-08-30 | 一种治疗骨质疏松的药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106237158A true CN106237158A (zh) | 2016-12-21 |
Family
ID=57599327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610812366.8A Pending CN106237158A (zh) | 2016-08-30 | 2016-08-30 | 一种治疗骨质疏松的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106237158A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102343027A (zh) * | 2011-10-18 | 2012-02-08 | 贵州同济堂制药有限公司 | 一种仙灵骨葆提取物,含其制剂及其制备方法 |
-
2016
- 2016-08-30 CN CN201610812366.8A patent/CN106237158A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102343027A (zh) * | 2011-10-18 | 2012-02-08 | 贵州同济堂制药有限公司 | 一种仙灵骨葆提取物,含其制剂及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2002122113A (ru) | Дроспиренон для гормональной заместительной терапии | |
JPH03209328A (ja) | 骨粗鬆症治療剤 | |
CN1728989A (zh) | 含植物雌激素的提取物选择性调节雌激素受体β的应用 | |
KR100406902B1 (ko) | 외상 치료 활성을 갖는 생약 추출물 및 이를 함유하는 건강식품 또는 동물용 사료 | |
AU3129701A (en) | A herbal composition and process for the manufacture of such composition for the management of gynaecological disorders | |
RU2188641C2 (ru) | Новые гормональные лекарственные препараты и их применение для коррекции эстрогенной недостаточности | |
CN1319569C (zh) | 治疗骨质疏松及骨折的中药制剂及其制备方法 | |
US20170014462A1 (en) | Bone and joint protection composition and use thereof | |
JP3228807B2 (ja) | 女性ホルモン上昇剤 | |
CN115154551B (zh) | 用于缓解胃部不适的含法莫替丁的药物组合物及其制备方法 | |
CN106237158A (zh) | 一种治疗骨质疏松的药物组合物 | |
CN102283917B (zh) | 一种用于治疗骨折的鹿骨药酒 | |
US11975052B2 (en) | Compound composition for improving bone health and preparation and application thereof | |
Shokrzadeh et al. | Prevention effects of Foeniculum vulgare (Fennel) hydroalcoholic extract for threatened abortion by misoprostol induction in experimental mice | |
RU2220712C1 (ru) | Средство и набор для нормализации функциональных нарушений, возникающих в предклимактерический и климактерический период | |
KR100222674B1 (ko) | 생약을 함유하는 칼슘 보충제 및 그 제조방법 | |
Kumar et al. | Potential of Cissus qudrangularis transdermal patch for fracture healing | |
RU2601112C1 (ru) | Способ восстановления хрящевой и костной ткани при остеопорозе | |
US11058737B2 (en) | Use of Euycoma longifolia extract in alleviating symptoms and/or conditions associated with hormonal imbalance in females | |
TW201834680A (zh) | 性早熟症的預防或改善用食品組合物及性早熟症的預防或治療用藥學組合物 | |
RU2801514C1 (ru) | Средство для коррекции нарушений менструального цикла, менопаузальных расстройств | |
US20020006446A1 (en) | Botanical combinations for treating AIDS and immune-deficient patients to maintain good health and the process for preparing the same | |
KR102376603B1 (ko) | 제니스테인 포스페이트 콘쥬게이트의 조성물의, 골량의 감소와 관련된 질환의 치료 또는 예방을 위한 사용 및 골 구조 및 골의 생체역학 강도를 개선하기 위한 사용 | |
CN102526405A (zh) | 一种加快骨折愈合的中药组合物 | |
CN106668865B (zh) | 用于治疗脑缺血的药物组合物、制剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190103 Address after: 274400 Panshi Office, Cao County, Heze City, Shandong Province Applicant after: Dong Zhiyong Address before: 264504 14, Lou Shan, Silver Beach, Rushan, Shandong. Applicant before: Lin Haiyan |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161221 |